Suven Life Sciences Limited — Board Meeting, 13-05-2026: Outcome of Board Meeting

Suven Life Sciences posted a consolidated Q4FY26 net loss of ₹45.60 Cr and FY26 net loss of ₹276.34 Cr. The Board approved these results. A key pipeline drug, SUVN-502, hit 76% enrollment in its global Phase 3 Alzheimer's trial, with results expected Q2/Q3 2027.